Yang Zhang1, Ying Xiao1, Yongtai Liu1, Quan Fang1, Zhuang Tian1, Jian Li2, Daobin Zhou2, Zhongpeng Xie3, Ruijia Dong1, Shuyang Zhang1. 1. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Department of Pathology, Hainan General Hospital, Haikou, China.
Abstract
Aims: Systemic light-chain (AL) amyloidosis is a multisystemic disorder leading to multiple organ dysfunction and mortality that is often caused by cardiac involvement. Soluble suppression of tumorigenicity 2 (sST2) is a novel biomarker identified for risk stratification of heart disease. The aim of this study was to investigate the value of circulating sST2 levels in prognosis and mortality risk assessments for the AL amyloidosis population. Methods and Results: A total of 56 patients diagnosed with AL amyloidosis were enrolled in Peking Union Medical College Hospital (PUMCH) from January 2015 to May 2018. The relationships between the clinical parameters and overall survival (OS) and risk factors for disease progression were assessed. Additionally, receiver operating characteristic (ROC) curves, Kaplan-Meier analysis, and Cox hazard models were performed to explore the predictive value of sST2 in mortality rates. We found that the median OS of all patients was 7.3 [interquartile range (IQR) 4.4, 15.9] months. The median baseline sST2 level was 12.2 (IQR 5.1, 31.1) ng/ml, and the sST2 high group had more severe patients with a higher Mayo stage. In the ROC analysis, the area under the curve (AUC) was 0.728 [95% confidence interval (CI) 0.603-0.853] for sST2 to predict the outcomes of AL amyloidosis patients, and the optimal cutoff value was 12.34 ng/ml (sensitivity 80.2%, specificity 61.1%). Moreover, in multivariate Cox proportional hazards regression analysis, sST2 acted as an independent predictor of poor functional outcome in patients with AL amyloidosis. Conclusion: In AL amyloidosis patients, sST2 was a strong and independent prognostic biomarker for all-cause mortality, providing complementary prognostic information of a novel scoring system for risk stratification.
Aims: Systemic light-chain (AL) amyloidosis is a multisystemic disorder leading to multiple organ dysfunction and mortality that is often caused by cardiac involvement. Soluble suppression of tumorigenicity 2 (sST2) is a novel biomarker identified for risk stratification of heart disease. The aim of this study was to investigate the value of circulating sST2 levels in prognosis and mortality risk assessments for the AL amyloidosis population. Methods and Results: A total of 56 patients diagnosed with AL amyloidosis were enrolled in Peking Union Medical College Hospital (PUMCH) from January 2015 to May 2018. The relationships between the clinical parameters and overall survival (OS) and risk factors for disease progression were assessed. Additionally, receiver operating characteristic (ROC) curves, Kaplan-Meier analysis, and Cox hazard models were performed to explore the predictive value of sST2 in mortality rates. We found that the median OS of all patients was 7.3 [interquartile range (IQR) 4.4, 15.9] months. The median baseline sST2 level was 12.2 (IQR 5.1, 31.1) ng/ml, and the sST2 high group had more severe patients with a higher Mayo stage. In the ROC analysis, the area under the curve (AUC) was 0.728 [95% confidence interval (CI) 0.603-0.853] for sST2 to predict the outcomes of AL amyloidosispatients, and the optimal cutoff value was 12.34 ng/ml (sensitivity 80.2%, specificity 61.1%). Moreover, in multivariate Cox proportional hazards regression analysis, sST2 acted as an independent predictor of poor functional outcome in patients with AL amyloidosis. Conclusion: In AL amyloidosispatients, sST2 was a strong and independent prognostic biomarker for all-cause mortality, providing complementary prognostic information of a novel scoring system for risk stratification.
Authors: Antoni Bayes-Genis; James L Januzzi; Hanna K Gaggin; Marta de Antonio; Shweta R Motiwala; Elisabet Zamora; Amparo Galán; Mar Domingo; Agustín Urrutia; Josep Lupón Journal: J Card Fail Date: 2014-11-03 Impact factor: 5.712
Authors: Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2010-12-22 Impact factor: 8.790
Authors: Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray Journal: J Am Coll Cardiol Date: 2010-01-19 Impact factor: 24.094
Authors: Rana Ghali; Raffaele Altara; William E Louch; Alessandro Cataliotti; Ziad Mallat; Abdullah Kaplan; Fouad A Zouein; George W Booz Journal: Hypertension Date: 2018-10 Impact factor: 10.190
Authors: James L Januzzi; W Frank Peacock; Alan S Maisel; Claudia U Chae; Robert L Jesse; Aaron L Baggish; Michelle O'Donoghue; Rahul Sakhuja; Annabel A Chen; Roland R J van Kimmenade; Kent B Lewandrowski; Donald M Lloyd-Jones; Alan H B Wu Journal: J Am Coll Cardiol Date: 2007-07-30 Impact factor: 24.094
Authors: Marco M Ochs; Thomas Fritz; Nisha Arenja; Johannes Riffel; Florian Andre; Derliz Mereles; Fabian Aus dem Siepen; Ute Hegenbart; Stefan Schönland; Hugo A Katus; Matthias G W Friedrich; Sebastian J Buss Journal: J Cardiovasc Magn Reson Date: 2017-11-09 Impact factor: 5.364
Authors: Zeyu Wang; Xin Pan; Hong Xu; You Wu; Xiaomin Jia; Yiling Fang; Yi Lu; Yawei Xu; Ji Zhang; Yang Su Journal: Front Cardiovasc Med Date: 2022-02-09